GlaxoSmithKline CEO Andrew Witty confirmed plans to step down in a year's time. Though insiders such as CFO Simon Dingemans will be considered for the job, an outsider candidate is more likely. "I believe

The split was prompted in part by GlaxoSmithKline's recent acquisition of the vaccines previously controlled by Novartis, which has allowed it to leapfrog both its rivals and become the new global #1.

a unit of GlaxoSmithKline. It will continue to market its current portfolio of approved HIV drugs including Sustiva, Reyataz and Atripla. The price of the deal could be up to $2.9bn depending on the future

GlaxoSmithKline was the latest global marketing giant to join the so-called "mediapalooza", an unprecedented wave of global media reviews, in which more than 20 global groups have called pitches. GSK'